BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32981267)

  • 21. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
    Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
    J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques.
    Nedjadi T; Al-Maghrabi J; Assidi M; Dallol A; Al-Kattabi H; Chaudhary A; Al-Sayyad A; Al-Ammari A; Abuzenadah A; Buhmeida A; Al-Qahtani M
    BMC Cancer; 2016 Aug; 16():653. PubMed ID: 27539085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma.
    Anderson JM; Ariga R; Govil H; Bloom KJ; Francescatti D; Reddy VB; Gould VE; Gattuso P
    Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):120-4. PubMed ID: 12777994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
    Ross JS; Sheehan CE; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman RP; Fisher HA; Rifkin MD; Muraca PJ
    Cancer; 1997 Jun; 79(11):2162-70. PubMed ID: 9179063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.
    Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A
    Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.
    Mostafa NA; Eissa SS; Belal DM; Shoman SH
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):41-6. PubMed ID: 22099935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human epidermal growth factor receptor 2 (HER-2) status evaluation in advanced gastric cancer using immunohistochemistry versus silver in situ hybridization.
    Kepil N; Batur S; Sonmez Wetherilt C; Erdamar Cetin S
    Bosn J Basic Med Sci; 2017 May; 17(2):109-113. PubMed ID: 27579854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
    Johnson CJ; Barry MB; Vasef MA; Deyoung BR
    Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):54-8. PubMed ID: 18091319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.
    García-García E; Gómez-Martín C; Angulo B; Conde E; Suárez-Gauthier A; Adrados M; Perna C; Rodríguez-Peralto JL; Hidalgo M; López-Ríos F
    Histopathology; 2011 Jul; 59(1):8-17. PubMed ID: 21771023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is Helicobacter pylori a poor prognostic factor for HER-2 SISH positive gastric cancer?
    Selcukbiricik F; Tural D; Erdamar S; Buyukunal E; Demirelli F; Serdengecti S
    Asian Pac J Cancer Prev; 2013; 14(5):3319-22. PubMed ID: 23803123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer.
    Koh YW; Lee HJ; Lee JW; Kang J; Gong G
    Mod Pathol; 2011 Jun; 24(6):794-800. PubMed ID: 21317877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
    Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
    Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of her-2/neu by chromogenic in situ hybridization on borderline (2+) immunohistochemistry cases in carcinoma breast.
    Asif M; Khadim MT; Mushtaq S; Mamoon N; Akhtar F; Ali Z
    Asian Pac J Cancer Prev; 2011; 12(1):211-4. PubMed ID: 21517259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.